BackgroundThe rapid spread of HBV has resulted in the emergence of new variants. These viral genotypes and variants, in addition to carcinogenic risk, can be key predictors of therapy response and out
Wa (G1P[8]), DS-1 (G2P[4]), and AU-1(G3P[9]) strains were used as references for genotype 1 (Wa-like), genotype 2 (DS-1 like), and genotype 3 (AU-1 like), respectively.
The most frequent genotype each year is indicated in bold. For 8 out of the 295 samples genotyping could not be performed due to very low sample concentration. In the last row the number of patients a
a. Year of strain isolation or deposition into the STEC Reference Center at Michigan State University. b. Unknown refers to missing data; HUS, hemolytic uremic syndrome.
